GlassScriptPhysician profile
Lindsay B Smith
NPI 1447616222
$13,822.88
in general payments reported to CMS, 2019-2025
38 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,243 · 2022: $2,901 · 2023: $2,794 · 2024: $3,334 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,640 · Education: $38.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,640.23 |
| Education | $38.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,356.51 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,316.83 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,214.68 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,039.34 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ironwood Pharmaceuticals, INC | $811.38 | 2021-2024 | Linzess |
| Ardelyx, INC. | $704.91 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $523.61 | 2022-2025 | |
| Evoke Pharma, INC. | $480.82 | 2021-2025 | Gimoti |
| Gilead Sciences, INC. | $471.52 | 2021-2025 | |
| Qol Medical, LLC | $431.58 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $407.70 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $339.35 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $330.21 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $318.28 | 2024-2025 | Voquezna |
| Celgene Corporation | $278.36 | 2021-2024 | Zeposia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $263.12 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Pfizer INC. | $257.38 | 2023-2025 | |
| Madrigal Pharmaceuticals | $170.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $141.86 | 2023-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $136.01 | 2021-2023 | |
| Glaxosmithkline, LLC. | $109.44 | 2023-2024 | Trelegy Ellipta |
| Braintree Laboratories, INC. | $105.14 | 2021-2025 | Suflave, Sutab |
| Daiichi Sankyo INC. | $99.34 | 2022 | |
| Intercept Pharmaceuticals, INC. | $87.19 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $71.97 | 2021-2022 | |
| Celltrion USA INC. | $60.05 | 2024 | Zymfentra |
| Intra-Sana Laboratories | $49.60 | 2022 | |
| Janssen Scientific Affairs, LLC | $42.65 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $38.87 | 2022 | |
| Boston Scientific Corporation | $29.11 | 2022-2024 | |
| Galderma Laboratories, L.P. | $23.68 | 2025 | Nemluvio |
| Ipsen Biopharmaceuticals, INC | $19.91 | 2023 | Bylvay |
| Exact Sciences Corporation | $18.08 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $16.04 | 2024 | |
| Paratek Pharmaceuticals, INC. | $15.32 | 2022 | |
| Organon LLC | $14.78 | 2024 | |
| Amgen INC. | $14.31 | 2021 | |
| Fresenius Kabi USA, LLC | $13.43 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.